Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biogen Pharmachem Industries Ltd has submitted its Annual Secretarial Compliance Report for FY 2025-26, verified by Practicing Company Secretaries firm Agrawal Kushal & Associates. The secretarial auditor examined compliance across multiple SEBI regulations including LODR 2015, Insider Trading Regulations, and Depositories Regulations. The report shows the company maintained compliance with Secretarial Standards (ICSI), adopted and updated all required SEBI policies with board approval, maintained a functional website with timely disclosures, conducted performance evaluations of the Board and committees, obtained prior Audit Committee approval for related party transactions, and complied with insider trading norms including maintaining Structural Digital Database. Annexure A and B show zero deviations and no outstanding compliance observations from previous reports. The report also notes the company completed a preferential share issuance of 25 crore shares to non-promoter group, receiving BSE listing and trading approvals in mid-2025.
Clean compliance report with no regulatory violations or penalties indicates good governance practices. Shareholders can view this as a positive sign that the company is maintaining proper SEBI regulatory compliance.